Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity.
Platelet adhesion to the injured vessel wall is essential in haemostasis and thrombosis. This process involves the interaction of the platelet glycoprotein Ib (GPIb) with surface bound von Willebrand factor (vWF). Since synthetic polycationic peptides of the general formula (Arg)n, (Lys)n or (Arg-Lys)n inhibit GPIb-vWF interaction, they were suggested as potential antithrombotics. Protamine sulphate is a highly cationic polypeptide, arginine accounting for approximately 60% of the primary sequence, utilized to neutralize the anticoagulant effect of heparin after cardiac surgery. We have investigated potential effects of protamine sulphate on the function of GPIb-vWF. Addition of protamine sulphate to platelet-rich plasma (PRP), reduced significantly the GPIb-vWF activity as assessed by ristocetin-induced platelet agglutination. When protamine sulphate was added to PRP containing heparin, even at clinically relevant neutralizing doses the GPIb-vWF activity was reduced by 20-30% (p < 0.001). Protamine sulphate in excess of heparin nearly abolished the activity. Furthermore, the direct effect of protamine sulphate on collagen-induced platelet thrombus formation in non-anticoagulated human blood was investigated by employing an ex-vivo parallel-plate perfusion chamber device. Protamine sulphate (200 microg/mL) reduced platelet-collagen adhesion at shear rates of 650 and 2600 sec(-1) by 40% (p< 0.004) and 45% (p < 0.0001), respectively. The corresponding platelet thrombus volumes were concomitantly reduced by 90% (p < 0.006) and 84% (p < 0.05). Our data are questioning the rationale for empirical repetitive protamine sulphate administration when so-called "heparin rebound" after cardiac surgery is suspected, since protamine sulphate in excess of heparin may impair the platelet GPIb-vWF interaction necessary for normal haemostasis.
Barstad
R M
RM
Nycomed Imaging AS, Oslo, Norway.
Stephens
R W
RW
Hamers
M J
MJ
Sakariassen
K S
KS
D000925:Anticoagulants / Q000494:pharmacology; D001780:Blood Coagulation Tests / Q000295:instrumentation; D001783:Blood Flow Velocity; D003094:Collagen; D004305:Dose-Response Relationship, Drug; D005337:Fibrin / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006384:Hemagglutination / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D010973:Platelet Adhesiveness / Q000187:drug effects; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011479:Protamines / Q000494:pharmacology*; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors / Q000378:metabolism; D012310:Ristocetin / Q000494:pharmacology; D013927:Thrombosis / Q000139:chemically induced; D014841:von Willebrand Factor / Q000037:antagonists & inhibitors / Q000378:metabolism*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D019038:Platelet Glycoprotein GPIb-IX Complex; D011479:Protamines; D011956:Receptors, Cell Surface; D014841:von Willebrand Factor; D012310:Ristocetin; D005337:Fibrin; D006493:Heparin; D003094:Collagen